CN102441154A - 一种治疗痛风的中药制剂 - Google Patents
一种治疗痛风的中药制剂 Download PDFInfo
- Publication number
- CN102441154A CN102441154A CN2011103933721A CN201110393372A CN102441154A CN 102441154 A CN102441154 A CN 102441154A CN 2011103933721 A CN2011103933721 A CN 2011103933721A CN 201110393372 A CN201110393372 A CN 201110393372A CN 102441154 A CN102441154 A CN 102441154A
- Authority
- CN
- China
- Prior art keywords
- radix
- blood
- preparation
- pain
- chinese medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000009636 Huang Qi Substances 0.000 claims abstract description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 5
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 239000002893 slag Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 37
- 241000756943 Codonopsis Species 0.000 claims description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 6
- 241000255791 Bombyx Species 0.000 claims description 5
- 241000237636 Pheretima Species 0.000 claims description 5
- 241000283956 Manis Species 0.000 claims description 4
- 241000522620 Scorpio Species 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000009490 scorpio Substances 0.000 claims description 4
- 230000037452 priming Effects 0.000 claims description 3
- 230000008901 benefit Effects 0.000 abstract description 4
- 235000012907 honey Nutrition 0.000 abstract description 3
- 239000000052 vinegar Substances 0.000 abstract description 3
- 235000021419 vinegar Nutrition 0.000 abstract description 3
- 241000213006 Angelica dahurica Species 0.000 abstract 2
- 241000758794 Asarum Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000255789 Bombyx mori Species 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 244000075634 Cyperus rotundus Species 0.000 abstract 1
- 235000016854 Cyperus rotundus Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000243684 Lumbricus Species 0.000 abstract 1
- 241000218378 Magnolia Species 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 235000010674 Prunella vulgaris Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 45
- 239000008280 blood Substances 0.000 description 45
- 208000002193 Pain Diseases 0.000 description 40
- 230000036407 pain Effects 0.000 description 36
- 230000000694 effects Effects 0.000 description 22
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 20
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 20
- 229940116269 uric acid Drugs 0.000 description 20
- 230000017531 blood circulation Effects 0.000 description 14
- 230000001737 promoting effect Effects 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 208000006820 Arthralgia Diseases 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 201000007227 lymph node tuberculosis Diseases 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 210000003371 toe Anatomy 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010018498 Goitre Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000003872 goiter Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- XNRNNGPBEPRNAR-JQBLCGNGSA-N thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O XNRNNGPBEPRNAR-JQBLCGNGSA-N 0.000 description 2
- 210000001113 umbilicus Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000004528 Catalpa ovata Species 0.000 description 1
- 235000010005 Catalpa ovata Nutrition 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 101000862089 Clarkia lewisii Glucose-6-phosphate isomerase, cytosolic 1A Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241001487808 Protobothrops mucrosquamatus Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241000199627 Rhynchonelliformea Species 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种治疗痛风的中药制剂，由下列成分配制而成：川朴9g，枳壳12g，苏子9g，乌药9g，党参9g，黄芪9g，茯苓15g，陈皮9g，白术9g，当归9g，三七3g，川芎9g，赤芍9g，全蝎6g，僵蚕15g，地龙9g，穿山甲(醋炙)3g，丹参(酒炒)9g，熟地黄12g，夏枯草15g，甘草(蜜炙)6g，白芷6g，防风9g，香附15g，细辛3g。取上述中药，加红枣二个、生姜二片为引药，加水1500ml，文火煎煮45分钟，捞渣过滤制成汤剂；每日一剂，早晚各服一次，14天一个疗程。本发明配方，药源丰富，价格低廉，服用方便，病人乐于接受。
Description
技术领域
本发明涉中药技术领域，具体是一种治疗痛风的中药制剂。
背景技术
痛风又称“高尿酸血症”，嘌呤代谢障碍，属于关节炎一种。痛风是人体内嘌呤的物质的新陈代谢发生紊乱，尿酸的合成增加或排出减少，造成高尿酸血症，血尿酸浓度过高时，尿酸以钠盐的形式沉积在关节、软骨和肾脏中，引起组织异物炎性反应，即痛风。由于尿酸在人体血液中浓度过高，在软组织如关节膜或肌腱里形成针状结晶，导致身体免疫系统过度反应(敏感)而造成痛苦的炎症。一般发作部位为大拇指关节，踝关节，膝关节等。长期痛风患者有发作于手指关节，甚至耳廓含软组织部分的病例。急性痛风发作部位出现红、肿、热、剧烈疼痛，一般多在子夜发作，可使人从睡眠中惊醒。痛风初期，发作多见于下肢。痛风可以出现肾脏损害。临床上降低尿酸浓度多采用西药控制，尿酸70％从肾脏排泄，往往西药又比较伤肾，长期服用会对人体造成伤害，中药治疗痛风逐步被患者所认可，中药治疗副作用小，效果比较稳定。
发明内容
本发明的目的在于提供一种治疗痛风效果好，见效快，副作用小的中药药物。
本发明技术方案：一种治疗痛风的中药制剂，由下列成分配制而成：川朴9g，枳壳12g，苏子9g，乌药9g，党参9g，黄芪9g，茯苓15g，陈皮9g，白术9g，当归9g，三七3g，川芎9g，赤芍9g，全蝎6g，僵蚕15g，地龙9g，穿山甲(醋炙)3g，丹参(酒炒)9g，熟地黄12g，夏枯草15g，甘草(蜜炙)6g，白芷6g，防风9g，香附15g，细辛3g。取上述中药，加红枣二个、生姜二片为引药，加水1500m1，文火煎煮45分钟，捞渣过滤制成汤剂；每日一剂，早晚各服一次，14天一个疗程。
本发明配方中各原料药功效如下：
川朴：又名厚朴，能行气消积；燥湿除满；降逆平喘。实验证明，厚朴酚与和厚朴酚在各种情况下抑制血栓烷B2形成，由花生四烯酸或胶原引起的细胞内Ca升高也被两者抑制。厚朴酚与和厚朴酚的抗血小板作用是由于对血栓烷B2和细胞内Ca流动的抑制。
枳壳：对心、脑、肾等血流量的影响麻醉犬静脉注射枳实注射液1ml/kg，有显著的增加脑血流量的作用。注射后脑血流量平均增加82.6±20.56ml/100g脑重/分钟(P＜0.01)。平均增加数相当于注射前脑血流量的86.4％。脑血管阻力指数平均降低0.428±0.12(P＜0.01)，有显着降低脑血管阻力的作用。
苏子：降气消痰，平喘，润肠。用于痰壅气逆，咳嗽气喘，肠燥便秘。苏子具有除痰降气，止咳定喘，润心肺，治胸闷气逆，大便不通功能。
乌药：行气止痛，温肾散寒。乌药对心肌有兴奋作用，其挥发油内服有兴奋心肌、加速回流循环、升压及发汗作用，亦有兴奋大脑皮质、促进呼吸作用，局部涂用可使血管扩张、血液循环加快、缓解复合肌肉痉挛性疼痛作用。《本草通玄》：理七情郁结，气血凝停，霍乱吐泻，痰食稽留。《玉楸药解》：破瘀泄满，止痛消胀。
党参：党参具有补中益气，健脾益肺的功效。用于脾肺虚弱，气短心悸，食少便溏，虚喘咳嗽。《本草从新》记载：“补中益气、和脾胃、除烦渴。中气微弱，用以调补，甚为平妥。”综上所述，党参增强机体免疫功能、增强造血功能、抗应激、强心、抗休克、调节血压、抗心肌缺血和抑制血小板聚集等作用。
黄芪：《本经》首言痈疽久败，排脓止痛，次言大风癞疾，五痔鼠瘘，皆用生者，以疏卫气之热。性虽温补，而能通调血脉，流行经络，可无碍于壅滞也。其治气虚盗汗自汗，及皮肤痛，是肌表之药。治咯血柔脾胃，是中州之药。治伤寒尺脉不至，补肾脏元气不足，及婴儿易感风邪，发热自汗诸病，皆用炙者，以实卫气之虚，乃上中下内外三焦药，即《本经》补虚之谓。
茯苓：茯苓性味甘淡平，入心、肺、脾经。具有渗湿利水，健脾和胃，宁心安神的功效。可治小便不利，水肿胀满，痰饮咳逆，呕逆，恶阻，泄泻，遗精，淋浊，惊悸，健忘等症。茯苓之利水，是通过健运脾肺功能而达到的，与其它直接利水的中药不同。
陈皮：理气开胃，燥湿化痰，治脾胃病。用于胸腹胀满等症。橘皮辛散通温，气味芳香，长于理气，能入脾肺，故既能行散肺气壅遏，又能行气宽中，用于肺气拥滞、胸膈痞满及脾胃气滞、脘腹胀满等症。
白术：健脾益气，燥湿利水，止汗，安胎。大鼠灌胃白术水煎液后其凝血酶原时间显著延长。健康人服用白术水煎液或乙醇浸出液后，其凝血酶原时间及凝血时间均显著延长。洁古云：白术除湿益燥，和中益气，利腰脐间血，除胃中热。
当归：补血；活血；调经止痛；润燥滑肠。主血虚诸证；月经不调；经闭；痛经；症瘕结聚。《本草正》：当归，其味甘而重，故专能补血，其气轻而辛，故又能行血，补中有动，行中有补，诚血中之气药，亦血中之圣药也。大约佐之以补则补，故能养营养血，补气生精，安五脏，强形体，益神志，凡有形虚损之病，无所不宜。佐之以攻则通，故能祛痛通便，利筋骨，治拘挛、瘫痪、燥、涩等证。营虚而表不解者，佐以柴、葛、麻、桂等剂，大能散表卫热，而表不敛者，佐以大黄之类，又能固表。惟其气辛而动，故欲其静者当避之，性滑善行，大便不固者当避之。凡阴中火盛者，当归能动血，亦非所宜，阴中阳虚者，当归能养血，乃不可少。若血滞而为痢者，正所当用，其要在动、滑两字；若妇人经期血滞，临产催生，及产后儿枕作痛，具当以此为君。
三七：扩张血管、降低血压，改善微循环，增加血流量，预防和治疗心脑组织缺血、缺氧症；止血、活血化瘀；双向调节血糖、降低血脂、胆固醇、抑制动脉硬化。
川芎：活血祛瘀作用广泛，适宜瘀血阻滞各种病症；祛风止痛，效用甚佳，可治头风头痛、风湿痹痛等症。昔人谓川芎为血中之气药，殆言其寓辛散、解郁、通达、止痛等功能。
赤芍：清热凉血，散瘀止痛。抗血栓形成作用，赤芍煎剂15-20g(生药)/kg给大鼠灌胃，使血栓形成时间明显延长，长度缩短，重量减轻；凝血酶原时间和白陶土部分凝血活酶时间延长，优球蛋白溶解时间缩短，表明对血凝有显著抑制作用。抗血小板聚集作用，赤芍提取物在体外对肾上腺素、二磷酸腺苷(ADP)、烙铁头蛇毒(TMVA)和花生四烯酸(AA)诱导的血小板聚集均有显著抑制作用，并使血小板粘附与血小板第三因子活性降低，血小板内含量升高。赤芍抗动脉硬化的机制可能与改善脂蛋白组分比值、降低血浆过氧化脂质、减少钙沉积于动脉壁，抑制血小板聚集，调节TXA2/PGI2平衡和激活腺苷酸环化酶而增加动脉壁内浓度等有关。
全蝎：息风镇痉，攻毒散结，通络止痛。.《山东中草药手册》：息风通络，镇痉。治血拴闭塞性脉管炎，淋巴结结核，骨关节结核，流行性腮腺炎。
僵蚕：熄风止痉祛风止痛化痰散结。僵蚕有抗凝作用，能抑制血小板的凝聚和血栓的形成。
地龙：通行经络，可用治热痹节肿赤痛；适当配伍也可治寒痹；配伍益气行血药常用于气虚血瘀，经络不利，偏瘫失语者。实验证明：地龙有溶栓和抗凝的作用，有可明显延长血小板血栓和纤维蛋白血栓形成时间，使血栓长度和干重减少，并降低血液粘度。
穿山甲：活血散结；通经下乳；消痈溃坚。主血瘀经闭；症瘕；风湿痹痛；乳汁不下；痈肿；瘰疬等症。
丹参：活血调经，祛瘀止痛，凉血消痈，清心除烦，养血安神。抗血栓形成，提高纤溶酶活性；延长出、凝血时间；抑制血小板聚集；改善血液流变学特性(血粘度降低、红细胞电泳时间缩短)。
熟地黄：补血滋润；益精填髓。《珍珠囊》：大补血虚不足，通血脉，益气力。《本草从新》：滋肾水，封填骨髓，利血脉，补益真阴聪耳明目，黑发乌须。又能补肺阴，上久泻，治劳伤风痹，阴亏发热，千咳痰嗽，气短喘促，胃中空虚觉馁，痘证心虚无脓，病后胫股酸痛，产后脐腹急疼，感证阴亏，无汗使闭，诸种动权，一切肝肾阴亏，虚损百病，为壮水之主药。
夏枯草：清火，明目，散结，消肿。用于目赤肿痛，目珠夜痛，头痛眩晕，瘰疬，瘿瘤，肿痛；甲状腺肿大，淋巴结结核，乳腺增生，高血压、高血糖、高血脂和高血粘。。《本草通玄》：夏枯草，补养厥阴血脉，又能疏通结气。
甘草：补脾益气，清热解毒，祛痰止咳，缓急止痛，调和诸药。
白芷：祛风湿，活血排脓，生肌止痛。解热、镇痛与抗炎作用：白芷或杭白芷煎剂15g(生药)/kg灌胃，对背部皮下注射蛋白胨所致发热的家兔有明显解热作用，其效优于0.1g/kg的阿司匹林.白芷煎剂、醚提取物和水提取物8g(生药)/kg灌胃，对小鼠醋酸扭体反应的抑制率分别为69.6％，52.86％和40.53％；小鼠热板法试验也使痛哿明显提高，白芷煎剂4g(生药)/kg灌胃，对二甲苯所鼓小鼠耳部炎症也有明显抑制作用.另有报道，白芷对夹尾和烫尾致痛无抑制作用.
防风：祛风解表，胜湿止痛，止痉定搐。有解热、镇痛、镇静和抗惊厥、抗炎、抗病原微生物等作用。
香附：理气解郁，调经止痛。镇痛作用用小鼠电盘刺激法，香附子20％醇提取物0.5毫升/20克体重皮下注射，能明显提高小鼠痛阈。
细辛：解表散寒；祛风止痛；温肺化饮；通窍。镇静、镇痛作用细辛挥发油有明显的中枢抑制作用，小剂量可使动物安静、驯服、自主活动减少；大剂量可使动物睡眠，并有明显的抗惊厥作用。细辛煎剂灌服也有镇痛作用。其较强的镇痛作用为其治疗头身痛、牙痛等的重要药理学基础。
本发明配方共奏祛风止痛，活血通络，滋养肝肾，破血逐瘀，活血散结之功效。诸药配伍合理，标本兼治，切合病机，治疗脑血栓具有较好的效果。
本发明配方，药源丰富，价格低廉，服用方便，病人乐于接受。
具体实施方式：
下面结合实施例对本发明作进一步说明：
实施例：一种治疗痛风的中药制剂，由下列成分配制而成：川朴9g，枳壳12g，苏子9g，乌药9g，党参9g，黄芪9g，茯苓15g，陈皮9g，白术9g，当归9g，三七3g，川芎9g，赤芍9g，全蝎6g，僵蚕15g，地龙9g，穿山甲(醋炙)3g，丹参(酒炒)9g，熟地黄12g，夏枯草15g，甘草(蜜炙)6g，白芷6g，防风9g，香附15g，细辛3g。取上述中药，加红枣二个、生姜二片为引药，加水1500ml，文火煎煮45分钟，捞渣过滤制成汤剂；每日一剂，早晚各服一次，14天一个疗程。
典型病例：
病例1：赵某某，男，45岁，公司经理。患者多年来经常出差，接待应酬多，经常饮食肉食、海鲜等食物，且大量饮酒，加之旅途劳累，2010年初开始时感小腿关节、足趾肿痛，因工作较忙，未曾介意。后来感觉饮酒或劳累、受寒之后疼痛加剧，小腿关节疼痛最为严重，开始以为是关节炎，用炎痛喜康、布洛芬等药一月有余未根治。后在医院检查，血尿酸高达898umol/L，确诊为“痛风”。服用本发明中药制剂一个疗程，疼痛减轻，血尿酸下降，继续服用2个疗程后，患者以上症状消失，血尿酸已接近正常，继续巩固一个疗程，随访一年，未复发。
病例2：王某，男性，32岁，某企业职工。患者手趾、手背反复性肿痛二年。患者平时性格豪爽，善于交友，朋友聚会饮酒较多，后发现酒后往往肿痛加剧，难以入睡，局部灼热红肿。后病发作到医院检查。查体：面红，左手指指红、肿、弯曲痛、功能受限。舌质红，，苔黄腻，脉弦滑数。化验：血沉：82mm/h，血尿酸：796umol/L。X线示：左手指关节有变形缺损，诊断为痛风。医生推荐服用本发明中药制剂一个疗程，疼痛减轻，继续服用2个疗程后，患者以上症状消失，血尿酸已接近正常，继续巩固一个疗程康复。
病例3：郭某某，48岁，男。2005年患痛风病，关节已经发生变形，活动不便，经常性全身手脚关节红肿、疼痛难忍。几年来看过多家医院，用过多种药物治疗，症状有所缓解，不久又会复发加重。后经人介绍，试用本发明中药制剂，一个疗程疼痛减轻，继续服用2个疗程后，疼痛消失，关节红肿消失，坚持治疗三个月康复，回访无复发。
病例4：王某，男，39岁。2007年开始患痛风病，在医院通过西药治疗控制住了。一年又犯病，体检尿酸650mol/ml，脚踝关节红肿疼痛，行动困难。后服用本发明中药制剂一个疗程，疼痛减轻，血尿酸下降，继续服用2个疗程后，患者以上症状消失，血尿酸已接近正常，连续服用三个月后康复，能正常参加工作，至今未复发。
病例5：袁某，男，患痛风病6年多，足趾肿胀疼痛难忍，多家医院治疗均未治愈，2010年通过朋友的介绍，开始服用本发明中药制剂一个疗程，疼痛减轻，血尿酸下降，继续服用2个疗程后，患者以上症状消失，血尿酸已接近正常，连续服用三个月后康复，能正常参加工作，至今未复发。
病例6：张某某，女，46岁，农民，痛风病史8年。膝关节、脚趾肿胀疼痛难忍，尿酸720mol/ml。本发明中药制剂一个疗程，疼痛减轻，继续服用2个疗程后，疼痛消失，血尿酸已接近正常，连续服用三个月后康复，至今未复发。
病例7：刘某某，男，33岁，痛风病史3年，左足及小腿疼痛，趾关节肿大，喝酒或阴天加重。多家医院治疗过，均未治愈，服用本发明中药制剂一个疗程，疼痛减轻，血尿酸下降，继续服用2个疗程后，患者以上症状消失，血尿酸已接近正常，连续服用三个月后康复，能正常参加工作，至今未复发。
Claims (1)
1.一种治疗痛风的中药制剂，其特征在于，由下列成分配制而成：川朴9g，枳壳12g，苏子9g，乌药9g，党参9g，黄芪9g，茯苓15g，陈皮9g，白术9g，当归9g，三七3g，川芎9g，赤芍9g，全蝎6g，僵蚕15g，地龙9g，穿山甲3g，丹参9g，熟地黄12g，夏枯草15g，甘草6g，白芷6g，防风9g，香附15g，细辛3g。取上述中药，加红枣二个、生姜二片为引药，加水1500ml，文火煎煮45分钟，捞渣过滤制成汤剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110393372.1A CN102441154B (zh) | 2011-11-23 | 2011-11-23 | 一种治疗痛风的中药制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110393372.1A CN102441154B (zh) | 2011-11-23 | 2011-11-23 | 一种治疗痛风的中药制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102441154A true CN102441154A (zh) | 2012-05-09 |
| CN102441154B CN102441154B (zh) | 2016-05-04 |
Family
ID=46004414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110393372.1A Expired - Fee Related CN102441154B (zh) | 2011-11-23 | 2011-11-23 | 一种治疗痛风的中药制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102441154B (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813748A (zh) * | 2012-09-02 | 2012-12-12 | 胡伟 | 一种治疗痛风病的中药组合物及应用 |
| CN103349685A (zh) * | 2013-07-19 | 2013-10-16 | 苏州市天灵中药饮片有限公司 | 一种包含赤芍的中药及其制备方法 |
| CN107875266A (zh) * | 2017-11-28 | 2018-04-06 | 高大朋 | 用于治疗痛风及痛风石的口服中药 |
| CN111920924A (zh) * | 2020-08-04 | 2020-11-13 | 深圳市宝安中医院（集团） | 一种降低尿酸的中药组合物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1428164A (zh) * | 2001-12-25 | 2003-07-09 | 申万灵 | 一种通栓活络胶囊 |
| CN1432402A (zh) * | 2002-01-11 | 2003-07-30 | 张芳 | 灵芝通经活络酒 |
| CN1634311A (zh) * | 2004-09-23 | 2005-07-06 | 陈玉兰 | 治疗类风湿性关节炎、股骨头坏死、强直性脊柱炎的药物 |
-
2011
- 2011-11-23 CN CN201110393372.1A patent/CN102441154B/zh not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1428164A (zh) * | 2001-12-25 | 2003-07-09 | 申万灵 | 一种通栓活络胶囊 |
| CN1432402A (zh) * | 2002-01-11 | 2003-07-30 | 张芳 | 灵芝通经活络酒 |
| CN1634311A (zh) * | 2004-09-23 | 2005-07-06 | 陈玉兰 | 治疗类风湿性关节炎、股骨头坏死、强直性脊柱炎的药物 |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813748A (zh) * | 2012-09-02 | 2012-12-12 | 胡伟 | 一种治疗痛风病的中药组合物及应用 |
| CN103349685A (zh) * | 2013-07-19 | 2013-10-16 | 苏州市天灵中药饮片有限公司 | 一种包含赤芍的中药及其制备方法 |
| CN107875266A (zh) * | 2017-11-28 | 2018-04-06 | 高大朋 | 用于治疗痛风及痛风石的口服中药 |
| CN111920924A (zh) * | 2020-08-04 | 2020-11-13 | 深圳市宝安中医院（集团） | 一种降低尿酸的中药组合物及其制备方法 |
| CN111920924B (zh) * | 2020-08-04 | 2022-04-01 | 深圳市宝安中医院（集团） | 一种降低尿酸的中药组合物及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102441154B (zh) | 2016-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102512632B (zh) | 一种治疗月经不调的中药组合物 | |
| CN100998722B (zh) | 一种治疗月经后期痛经的内服中药 | |
| CN102441154A (zh) | 一种治疗痛风的中药制剂 | |
| CN104055980A (zh) | 治病养生中药泡脚水 | |
| CN103520366A (zh) | 用于治疗中风后痉挛性偏瘫的中药 | |
| CN102512552B (zh) | 一种治疗外感发热的中药组合物 | |
| CN105250890A (zh) | 一种治疗高脂血症中药 | |
| CN102488768B (zh) | 治疗痛风的中药药物 | |
| CN102430105B (zh) | 一种治疗慢性胃炎的中药组合物 | |
| CN102406743B (zh) | 一种治疗脑血栓的中药制剂 | |
| CN103463588B (zh) | 一种治疗中气下陷的中药组合物 | |
| CN103041145B (zh) | 一种治疗外感发热的中药组合物 | |
| CN102430030B (zh) | 一种治疗骨痹的中药组合物 | |
| CN103212039B (zh) | 一种治疗小儿气虚咳嗽的中药组合物 | |
| CN101085330A (zh) | 一种内服治疗高血脂的中药组合物 | |
| CN100998729A (zh) | 一种治疗血虚型便秘的内服中药 | |
| CN104432386A (zh) | 一种防治腰膝酸软、筋骨无力的桑寄生口服液及其制备方法 | |
| CN109646483A (zh) | 一种调理血瘀体质的中药泡浴抑菌液/颗粒及制备与使用方法 | |
| CN103127283A (zh) | 一种治疗盆腔炎的药物 | |
| CN103028063B (zh) | 一种治疗肾病的中药组合物 | |
| CN101244209B (zh) | 预防或治疗心脑血管疾病的药物 | |
| CN1994415B (zh) | 一种治疗痛经的内服中药 | |
| CN105663679A (zh) | 一种治疗鱼鳞病的中药组合物 | |
| CN102764326B (zh) | 一种治疗冠心病的中药组合物 | |
| CN101130027A (zh) | 一种内服治疗高血脂的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120509 |
|
| CI01 | Publication of corrected invention patent application |
Correction item: deemed withdrawal of patent application after publication Correct: The revocation of the patent application shall be deemed to be withdrawn False: The withdrawal of the patent application shall be deemed to be withdrawn Number: 26 Volume: 31 |
|
| ERR | Gazette correction | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160504 Termination date: 20161123 |